Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI. However, pneumonia incidence was higher in the inhale...

Descripción completa

Detalles Bibliográficos
Autores principales: Dransfield, Mark T., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, LaFon, David, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert A., Lange, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086537/
https://www.ncbi.nlm.nih.gov/pubmed/33108212
http://dx.doi.org/10.1513/AnnalsATS.202002-096OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086537/
https://www.ncbi.nlm.nih.gov/pubmed/33108212
http://dx.doi.org/10.1513/AnnalsATS.202002-096OC

Ejemplares similares